A Phase 3 interventional study of Chloroprocaine and Ropivacaine in Unplanned Caesarean Section, sponsored by Sintetica SA. Terminated at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.
Sponsored by Sintetica SA · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study evaluate the quality of epidural anaesthesia and the safety of Chloroprocaine HCl 3% compared with Ropivacaine HCl 0.75% in patients with an epidural catheter in situ undergoing unplanned Caesarean section.
Labouring women who have an epidural catheter in situ and established analgesia, in need of an unplanned Caesarean section, will be randomly allocated to receive either Chloroprocaine HCl 3% (T-group) or Ropivacaine HCl 0.75% (R-group) epidurally. Prior to the epidural injection, the patient will be transferred to the operating theatre. The local anaesthetic solution will be freshly prepared and 20 mL will be administered by epidural injection, according to the standard hospital procedures, as detailed in the "Study Schedule" section below. Time T0 is defined as the start time of the first epidural injection of the investigational product. In case of pain or discomfort, a 6 mL epidural top-up of the same anaesthetic, i.e. Chloroprocaine HCl 3% in T-group and Ropivacaine HCl 0.75% in R-group, will be administered. The anaesthesiologist(s) administering the anaesthetic and collecting the data will be blinded with respect to the treatment given to each patient.
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
Drug: Chloroprocaine
Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
Drug: Ropivacaine
The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
Also known as: Ampres
The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
Also known as: Naropin
Time to the Onset of Anaesthesia
The time from T0 (start time of the epidural injection) to complete loss of cold sensation to the metameric level T4 (block to T4), bilateral.
Time frame: Up to 1 hour after last epidural injection
Time From T0 to Loss Light Touch Sensation
Time from T0 to loss light touch sensation to the metameric level T5 (block to T5), bilateral
Time frame: Up to 1 hour after last epidural injection
Quality of the Block
Quality of the block assessed between 10 and 20 min after the end of surgery by the anaesthesiologist and patient together using a 0-10 cm visual analogue scale (VAS; 10=excellent anaesthetic quality, 0=very poor anaesthetic quality)
Time frame: Quality of the block assessed between 10 and 20 minutes after the end of surgery
Maximum Metameric Level of the Sensory Block
Maximum metameric level of the sensory block assessed by three modalities (complete loss of cold, pinprick and light touch sensation)
Time frame: Up to 1 hrs after last epidural injection
Motor Block Assessment
Motor block assessment (modified Bromage scale) at baseline, prior to incision and after surgery
Time frame: Up to 12 hours after surgery
Proportion of Patients Who Need Top-up Anaesthesia
Proportion of patients who need top-up epidural anaesthesia (same anaesthetic as first epidural injection)
Time frame: Up to 2 hours after last epidural injection
Proportion of Patients Who Need Supplementation of Opioids
Proportion of patients who need supplementation of the block intraoperatively with intravenous opioids
Time frame: Up to 2 hours after last epidural injection
Proportion of Patients Who Need General Anaesthesia
Proportion of patients who need general anaesthesia
Time frame: Up to 2 hours after last epidural injection
Discomfort and Pain During Surgery
Discomfort and pain assessed during surgery through spontaneous patient's reporting and questioning by the Investigator/anaesthesiologist
Time frame: Up to 2 hours after last epidural injection
First Breakthrough Pain
First breakthrough pain assessed by the patient, recorded on a 0-10 cm VAS (0=no pain, 10= most severe pain imaginable)
Time frame: Up to 12 hours after surgery
Maternal Treatment-emergent Adverse Events
Maternal treatment-emergent adverse events, with particular attention to pain (see above), pruritus, nausea, vomiting
Time frame: Up to day 3±1 after surgery
Pulse Rate
Maternal pulse rate
Time frame: Up to 12 hours after surgery
Oximetry
Maternal pulse oximetry (SpO2)
Time frame: Up to 12 hours after surgery
Electrocardiogram
Maternal electrocardiogram
Time frame: Up to 12 hours after surgery
Total Dose of Phenylephrine
Total dose (μg) of phenylephrine
Time frame: Up to 2 hours after last epidural injection
Total Dose of Atropine
Total dose (mg) of atropine
Time frame: Up to 2 hours after last epidural injection
Intravenous Fluids
Total volume (ml) of intravenous fluids
Time frame: Up to 12 hours after surgery
Neonate Apgar
Neonate Apgar scores at 1 and 5 minutes
Time frame: 1 and 5 minutes after birth
Foetal Hypoxic Stress
Indication of foetal hypoxic stress
Time frame: Up to 12 hours after surgery
Pain at the Site of Surgery
Pain at the site of surgery at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=most severe pain imaginable)
Time frame: Up to 12 hours after surgery
Pain at the Site of Epidural Injection
Pain at the site of epidural injection at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=severe pain)
Time frame: Up to 12 hours after surgery
Concomitant Medications
Maternal concomitant medications
Time frame: Up to day 3±1 after surgery
Neonatal Adverse Events
Neonatal adverse events
Time frame: Up to day 3±1 after surgery
Due to difficulties in enrolling patients, the enrolment stopped prematurely, and only 16 patients were screened and randomised (only at site N. 001).
| Milestone | Chloroprocaine | Ropivacaine |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
The time from T0 (start time of the epidural injection) to complete loss of cold sensation to the metameric level T4 (block to T4), bilateral.
| minutes | Chloroprocaine | Ropivacaine |
|---|---|---|
| Time to the Onset of Anaesthesia | 9 ± 5.8 | 9.1 ± 4 |
Time from T0 to loss light touch sensation to the metameric level T5 (block to T5), bilateral
| minutes | Chloroprocaine | Ropivacaine |
|---|---|---|
| Time From T0 to Loss Light Touch Sensation | 9.3 ± 9.2 | 13.3 ± 4.1 |
Quality of the block assessed between 10 and 20 min after the end of surgery by the anaesthesiologist and patient together using a 0-10 cm visual analogue scale (VAS; 10=excellent anaesthetic quality, 0=very poor anaesthetic quality)
| units on a scale | Chloroprocaine | Ropivacaine |
|---|---|---|
| Quality of the Block | 9.8 ± 0.4 | 8.4 ± 3.7 |
Maximum metameric level of the sensory block assessed by three modalities (complete loss of cold, pinprick and light touch sensation)
Results for this outcome have not been posted.
Motor block assessment (modified Bromage scale) at baseline, prior to incision and after surgery
Results for this outcome have not been posted.
Proportion of patients who need top-up epidural anaesthesia (same anaesthetic as first epidural injection)
Results for this outcome have not been posted.
Proportion of patients who need supplementation of the block intraoperatively with intravenous opioids
Results for this outcome have not been posted.
Proportion of patients who need general anaesthesia
Results for this outcome have not been posted.
Discomfort and pain assessed during surgery through spontaneous patient's reporting and questioning by the Investigator/anaesthesiologist
Results for this outcome have not been posted.
First breakthrough pain assessed by the patient, recorded on a 0-10 cm VAS (0=no pain, 10= most severe pain imaginable)
Results for this outcome have not been posted.
Maternal treatment-emergent adverse events, with particular attention to pain (see above), pruritus, nausea, vomiting
Results for this outcome have not been posted.
Maternal pulse rate
Results for this outcome have not been posted.
Maternal pulse oximetry (SpO2)
Results for this outcome have not been posted.
Maternal electrocardiogram
Results for this outcome have not been posted.
Total dose (μg) of phenylephrine
Results for this outcome have not been posted.
Total dose (mg) of atropine
Results for this outcome have not been posted.
Total volume (ml) of intravenous fluids
Results for this outcome have not been posted.
Neonate Apgar scores at 1 and 5 minutes
Results for this outcome have not been posted.
Indication of foetal hypoxic stress
Results for this outcome have not been posted.
Pain at the site of surgery at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=most severe pain imaginable)
Results for this outcome have not been posted.
Pain at the site of epidural injection at final visit/early termination visit, recorded on a 0-10 cm VAS (0=no pain, 10=severe pain)
Results for this outcome have not been posted.
Maternal concomitant medications
Results for this outcome have not been posted.
Neonatal adverse events
Results for this outcome have not been posted.
Collected over Maternal AEs will be assessed throughout the study from the signature of the informed consent up to follow-up Visit Day 3±1. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chloroprocaine | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Ropivacaine | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | Chloroprocaine | Ropivacaine |
|---|---|---|
| HypotensioVascular disorders | 5/8 | 7/8 |
| procedural painInjury, poisoning and procedural complications | 1/8 | 2/8 |
| anemiaBlood and lymphatic system disorders | 1/8 | 2/8 |
| post lumbar puncture syndromInjury, poisoning and procedural complications | 1/8 | 0/8 |
| POst procedural disconfortInjury, poisoning and procedural complications | 1/8 | 0/8 |
| procedural nauseaInjury, poisoning and procedural complications | 1/8 | 0/8 |
| dysphagiaGastrointestinal disorders | 0/8 | 1/8 |
| vomitingGastrointestinal disorders | 0/8 | 1/8 |
| nauseaGastrointestinal disorders | 1/8 | 1/8 |
| urinary tract infectionInfections and infestations | 0/8 | 1/8 |
| Age, Continuous(years) | Chloroprocaine | Ropivacaine | Total |
|---|---|---|---|
| Mean | 28.8 ± 5.6 | 33.3 ± 7.5 | 31.05 ± 6.55 |
| Sex: Female, Male(Participants) | Chloroprocaine | Ropivacaine | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Chloroprocaine | Ropivacaine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 7 | 6 | 13 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Chloroprocaine | Ropivacaine | Total |
|---|---|---|---|
| Belgium | 8 | 8 | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Jun 2021, 56 months.
Results were first posted in Nov 2023, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA